Delta variant lowers COVID-19 vaccine effectiveness to 66%; Johnson & Johnson reports booster shot results; cancer center reports mask, vaccine preferences of patients.
As the Delta variant spread, COVID-19 vaccine effectiveness dropped from 90% to approximately 66%, according to a report from the CDC Tuesday. The first analysis from the ongoing HEROES-RECOVER study, which includes more than 4000 health care workers and other frontline workers in 6 states, looked at vaccine effectiveness estimates from December 14, 2020, to April 10, 2021, before the Delta variant; the latest figure updates the testing period to August 14. Researchers emphasized that a 66% effectiveness rate shows that vaccines are still protecting people from contracting the virus, STAT News reported.
Receiving a booster shot of the Johnson & Johnson (J&J) vaccine dramatically increases the levels of antibodies against COVID-19, the company reported Wednesday. Multiple studies suggest higher levels of antibodies are linked to higher rates of protection, especially against the Delta variant. However, the lack of data regarding other parts of the immune system like T cells means there is not a precise estimate on the effectiveness of the booster shot against COVID-19. The New York Times said J&J will submit the data to the FDA and, if authorized, the Biden administration may provide booster shots 8 months after initial vaccination.
Patients with cancer overwhelmingly prefer that their health care providers are vaccinated against COVID-19 and wear masks, according to a survey conducted by Florida Cancer Specialists & Research Institute (FCS). The online survey included more than 6800 patients with cancer to assess patient reaction to FCS’s recent mandate for physicians and employees to be fully vaccinated for COVID-19 by October 1, 2021, with the first dose being administered no later than August 31, 2021. The majority (88%) said it was important to them that FCS physicians, nurses and staff are fully vaccinated against COVID-19, and 67% said it was “extremely important.” Regardless if they are vaccinated, 88% also said it was important that their FCS providers wear a mask.
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More